Latest Prasugrel Stories

2009-08-31 09:43:16

Studies from a growing body of convincing data show that responsiveness to antiplatelet therapy is real. This is a clinically important issue and there is a need to develop individual antiplatelet strategies particularly for patients at risk.

2009-08-31 08:43:55

Data from a phase II trial of an investigational intravenous drug designed to block the formation of blood clots shows potential to reduce the risk of death, a second heart attack, or other coronary complications compared with the current standard of care in patients presenting with acute coronary syndromes (heart attacks or unstable angina).

2009-08-24 07:00:00

SOUTH SAN FRANCISCO, Calif., Aug. 24 /PRNewswire/ -- Portola Pharmaceuticals, Inc.

2009-08-05 08:00:00

PARSIPPANY, N.J. and INDIANAPOLIS, Aug. 5 /PRNewswire-FirstCall/ -- Effient(TM) (prasugrel), a new antiplatelet medicine, is now available in pharmacies across the United States, Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) announced today. The U.S.

2009-07-14 07:30:00

SAN DIEGO, July 14 /PRNewswire/ -- With the recent FDA approval of the new P2Y12 inhibitor, prasugrel (Effient), Accumetrics, Inc. announces that its VerifyNow P2Y12 Test is not only able to assess response to Plavix(R), but also its newly approved competitor, Effient.

2009-07-10 15:43:00

PARSIPPANY, N.J. and INDIANAPOLIS, July 10 /PRNewswire-FirstCall/ -- Daiichi Sankyo, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the U.S.

2009-07-10 08:06:00

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc.

2009-05-21 08:00:00

Universal Definition of Myocardial Infarction provided jointly by leading international cardiology societies TOKYO and INDIANAPOLIS, May 21 /PRNewswire-FirstCall/ -- Investigators from the Phase III TRITON-TIMI 38 study applied the new classification system for the Universal Definition of Myocardial Infarction to the results of the study and showed that patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) and taking prasugrel, as compared with...

2009-05-14 09:47:55

Patients with peripheral artery disease (PAD) could benefit from taking aspirin. A new study reveals the medication may lower the risk of stroke in these patients.

2009-05-05 06:00:00

TOKYO and INDIANAPOLIS, Ind., May 5 /PRNewswire-FirstCall/ -- A new substudy from 1,466 patients from the Phase III TRITON-TIMI 38 clinical trial showed that patients who took prasugrel and had a reduced function of the CYP2C19 gene did not have an increased risk of cardiovascular death, heart attack or stroke compared with those patients who had normal function.

Word of the Day
  • Stoppage; cessation (of labor).
  • A standing still or idling (of mills, factories, etc.).
The word chomage comes into English from French.]